Institut Català de la Salut
[Beaulieu ME, Castillo F] Peptomyc, Barcelona, Spain. [Soucek L] Peptomyc, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-09-01T11:04:56Z
2021-09-01T11:04:56Z
2020-04-22
Myc; descobriment de fàrmacs; Interaccions proteïna-ADN
Myc; Descubrimiento de fármacos; Interacciones proteína-ADN
Myc; Drug discovery; Protein–DNA interactions
Myc is a transcription factor driving growth and proliferation of cells and involved in the majority of human tumors. Despite a huge body of literature on this critical oncogene, our understanding of the exact molecular determinants and mechanisms that underlie its function is still surprisingly limited. Indubitably though, its crucial and non-redundant role in cancer biology makes it an attractive target. However, achieving successful clinical Myc inhibition has proven challenging so far, as this nuclear protein is an intrinsically disordered polypeptide devoid of any classical ligand binding pockets. Indeed, Myc only adopts a (partially) folded structure in some contexts and upon interacting with some protein partners, for instance when dimerizing with MAX to bind DNA. Here, we review the cumulative knowledge on Myc structure and biophysics and discuss the implications for its biological function and the development of improved Myc inhibitors. We focus this biophysical walkthrough mainly on the basic region helix–loop–helix leucine zipper motif (bHLHLZ), as it has been the principal target for inhibitory approaches so far.
This research was funded by the European Commission (SME Instrument, Grant no. 872212) and European Research Council (CoG grant no. 617473).
Article
Versió publicada
Anglès
Medicaments - Desenvolupament; ADN - Interaccions de les proteïnes; Oncogens; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Basic Helix-Loop-Helix Transcription Factors::Proto-Oncogene Proteins c-myc; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Intrinsically Disordered Proteins; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Drug Development::Drug Evaluation, Preclinical; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de unión al ADN::factores de transcripción con hélice-asa-hélice básico::proteínas protooncogénicas c-myc; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas intrínsecamente desestructuradas; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::desarrollo de medicamentos::evaluación preclínica de medicamentos
MDPI
Cells;9(4)
https://www.mdpi.com/2073-4409/9/4/1038
info:eu-repo/grantAgreement/EC/H2020/872212
info:eu-repo/grantAgreement/EC/H2020/617473
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/